There are currently 49 active clinical trials seeking participants for NSCLC research studies. The states with the highest number of trials for Autism participants are California, New York, Florida and Texas.
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
NCT05180799
Recruiting
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +8 locations
Conditions: Solid Tumor, Adult, NSCLC, Urothelial Carcinoma, Gastric Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Cervical Carcinoma, Melanoma, Renal Cell Carcinoma, Carcinoma
Register for Updates
Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC)
NCT05983432
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: SystImmune Recruiting Center, Port Saint Lucie, Florida +5 locations
Conditions: Non Small Cell Lung Cancer, NSCLC, Lung Cancer
Register for Updates
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
NCT05657873
Recruiting
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistanc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT05500508
Recruiting
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/18/2023
Locations: Mayo Clinic - Arizona, Phoenix, Arizona +6 locations
Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Register for Updates
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Northwestern University Robert H Lurie Medical Research, Chicago, Illinois +3 locations
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
NCT04712877
Recruiting
This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer. The primary purpose of this testing is to determine the presence of 10 oncogenic drivers (mutations i... Read More
Gender:
All
Ages:
All
Trial Updated:
09/08/2023
Locations: University of California, Davis, Davis, California +14 locations
Conditions: NSCLC
Register for Updates
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05002270
Recruiting
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Mayo Clinc, Phoenix, Arizona +3 locations
Conditions: Advanced Solid Tumor, NSCLC, CRC
Register for Updates
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT04370587
Recruiting
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +8 locations
Conditions: Melanoma, Solid Tumor, NSCLC, HNSCC, Sarcoma, Squamous Cell Carcinoma
Register for Updates
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
NCT02905591
Recruiting
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the standard therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: Holden Comprehensive Cancer Cener, Iowa City, Iowa
Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: University of Birmingham Alabama, Birmingham, Alabama +52 locations
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
NCT04720976
Recruiting
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2023
Locations: Research Site, Phoenix, Arizona +14 locations
Conditions: Solid Tumor, NSCLC
Register for Updates